Select a patient below to see how GLIVEC extends survival in patients with KIT+ GIST
In KIT+ GIST, GLIVEC is a key partner in the patient journey
Historically, GIST was a poorly characterized disease entity, frequently misdiagnosed as smooth muscle tumour.1 Research advances and implementation of new technologies have transformed our knowledge of GIST in terms of cellular and molecular etiology, diagnostic strategies, and treatment options.2
References: 1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83. 2. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465.